Anti-SIRP alpha antibodies as a potential new tool for cancer immunotherapy
2017 (English)In: JCI Insight, ISSN 2379-3708, Vol. 2, no 1, e89140Article in journal (Refereed) Published
Tumor cells are thought to evade immune surveillance through interaction with immune cells. Much recent attention has focused on the modification of immune responses as a basis for new cancer treatments. SIRP alpha is an Ig superfamily protein that inhibits phagocytosis in macrophages upon interaction with its ligand CD47 expressed on the surface of target cells. Here, we show that SIRP alpha is highly expressed in human renal cell carcinoma and melanoma. Furthermore, an anti-SIRP alpha Ab that blocks the interaction with CD47 markedly suppressed tumor formation by renal cell carcinoma or melanoma cells in immunocompetent syngeneic mice. This inhibitory effect of the Ab appeared to be mediated by dual mechanisms: direct induction of Ab-dependent cellular phagocytosis of tumor cells by macrophages and blockade of CD47-SIRP alpha signaling that negatively regulates such phagocytosis. The antitumor effect of the Ab was greatly attenuated by selective depletion not only of macrophages but also of NK cells or CD8(+) T cells. In addition, the anti-SIRP alpha Ab also enhances the inhibitory effects of Abs against CD20 and programmed cell death 1 (PD-1) on tumor formation in mice injected with SIRP alpha-nonexpressing tumor cells. Anti-SIRP alpha Abs thus warrant further study as a potential new therapy for a broad range of cancers.
Place, publisher, year, edition, pages
American Society for Clinical Investigation , 2017. Vol. 2, no 1, e89140
Cancer and Oncology Basic Medicine
IdentifiersURN: urn:nbn:se:umu:diva-132153DOI: 10.1172/jci.insight.89140ISI: 000393591600003PubMedID: 28097229OAI: oai:DiVA.org:umu-132153DiVA: diva2:1079572
Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy2017-03-082017-03-082017-03-08Bibliographically approved